Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 12/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GNRHR | P30968 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1457426 | 0.88 | GPR119 (0.41) | GPR119MEN1KMT2AGNRHRMAPT | |
| SCHEMBL12825427 | 0.85 | SMN1; SMN2 (0.56) | GPR119NAMPTMEN1KMT2ACYP2C19 | |
| SCHEMBL2400325 | 0.83 | GPR119 (0.54) | GPR119NAMPTMEN1KMT2ACYP2C19 | |
| SCHEMBL5113754 | 0.82 | GPR119 (0.53) | GPR119NAMPTMEN1KMT2ACYP2C19 | |
| SCHEMBL5114594 | 0.82 | SMN1; SMN2 (0.57) | GPR119NAMPTMEN1KMT2ACYP2C19 | |
| SCHEMBL2399119 | 0.82 | POLB (0.44) | KMT2ASMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL2400827 | 0.81 | KMT2A (0.40) | MEN1KMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL1457656 | 0.81 | CYP1A2 (0.48) | MEN1KMT2ACYP2C19SMN1; SMN2MAPT | |
| SCHEMBL5126254 | 0.80 | GPR119 (0.54) | GPR119NAMPTMEN1KMT2ACYP2C19 | |
| SCHEMBL1457289 | 0.80 | ALDH1A1 (0.39) | NAMPTSMN1; SMN2MAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2292625-A1 | Substituted spiro compounds and their use for producing pain-relief medicaments | Grünenthal GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | REN, PKD1, NR3C2 | GPR119 2131/4885NAMPT 319/4885MEN1 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.